These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 1577671)

  • 21. Letter: Electronegative groups at C-3 of rifamycin S enhance its activity toward DNA-dependent RNA polymerase.
    Dampier MF; Whitlock HW
    J Am Chem Soc; 1975 Oct; 97(21):6254-6. PubMed ID: 1176735
    [No Abstract]   [Full Text] [Related]  

  • 22. Specific Interactions between Rifamycin Antibiotics and Water Influencing Ability To Overcome Natural Cell Barriers and the Range of Antibacterial Potency.
    Pyta K; Janas A; Skrzypczak N; Schilf W; Wicher B; Gdaniec M; Bartl F; Przybylski P
    ACS Infect Dis; 2019 Oct; 5(10):1754-1763. PubMed ID: 31461259
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comprehensive study on structure-activity relationships of rifamycins: discussion of molecular and crystal structure and spectroscopic and thermochemical properties of rifamycin O.
    Bacchi A; Pelizzi G; Nebuloni M; Ferrari P
    J Med Chem; 1998 Jun; 41(13):2319-32. PubMed ID: 9632365
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Allosteric modulation of the RNA polymerase catalytic reaction is an essential component of transcription control by rifamycins.
    Artsimovitch I; Vassylyeva MN; Svetlov D; Svetlov V; Perederina A; Igarashi N; Matsugaki N; Wakatsuki S; Tahirov TH; Vassylyev DG
    Cell; 2005 Aug; 122(3):351-63. PubMed ID: 16096056
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rifamycin-mode of action, resistance, and biosynthesis.
    Floss HG; Yu TW
    Chem Rev; 2005 Feb; 105(2):621-32. PubMed ID: 15700959
    [No Abstract]   [Full Text] [Related]  

  • 26. [New derivatives of rifamycin SV. Esters, hydrazide amides of 3-carboxyrifamycin SV].
    Marchi E; Brufani M; Bellomo P
    G Ital Chemioter; 1979; 26(1-2):207-12. PubMed ID: 554811
    [No Abstract]   [Full Text] [Related]  

  • 27. Rifampicin-resistant bacteriophage PBS2 infection and RNA polymerase in Bacillus subtilis.
    Price AR; Hitzeman R; Frato J; Lombardi K
    Nucleic Acids Res; 1974 Nov; 1(11):1497-502. PubMed ID: 10793705
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Specific inhibition of a primer-dependent nucleotide chain elongation reaction by the rifamycin derivative AF/013.
    Jacob ST; Rose KM; Glaser JM
    Arch Biochem Biophys; 1974 Oct; 164(2):771-3. PubMed ID: 4376670
    [No Abstract]   [Full Text] [Related]  

  • 29. Multiple effects of rifamycin derivatives on animal-cell metabolism of macromolecules.
    Busiello E; Di Girolamo A; Di Girolamo M; Fischer-Fantuzzi L; Vesco C
    Eur J Biochem; 1973 Jun; 35(2):251-8. PubMed ID: 4736920
    [No Abstract]   [Full Text] [Related]  

  • 30. CGP 4832, a new semisynthetic rifamycin derivative highly active against some gram-negative bacteria.
    Wehrli W; Zimmermann W; Kump W; Tosch W; Vischer W; Zak O
    J Antibiot (Tokyo); 1987 Dec; 40(12):1733-9. PubMed ID: 2448280
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rifamycin inhibition of WT and Rif-resistant Mycobacterium tuberculosis and Escherichia coli RNA polymerases in vitro.
    Gill SK; Garcia GA
    Tuberculosis (Edinb); 2011 Sep; 91(5):361-9. PubMed ID: 21704562
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mechanism of action of rifamazine, a member of a new class of (dimeric) rifamycins.
    Fietta AM; Silvestri LG
    Eur J Biochem; 1975 Mar; 52(2):391-400. PubMed ID: 51795
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Conformational variety for the ansa chain of rifamycins: comparison of observed crystal structures and molecular dynamics simulations.
    Bacchi A; Pelizzi G
    J Comput Aided Mol Des; 1999 Jul; 13(4):385-96. PubMed ID: 10425603
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mechanism of action of a rifamycin derivative (AF-013) which is active on the nucleic acid polymerases insensitive to rifampicin.
    Riva S; Fietta A; Silvestri LG
    Biochem Biophys Res Commun; 1972 Dec; 49(5):1263-71. PubMed ID: 4566674
    [No Abstract]   [Full Text] [Related]  

  • 35. Diffusion-enhanced energy transfer shows accessibility of ribonucleic acid polymerase inhibitor binding sites.
    Meares CF; Rice LS
    Biochemistry; 1981 Feb; 20(3):610-7. PubMed ID: 7011368
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Resistance in inhibitors of RNA polymerase in actinomycetes which produce them.
    Blanco MG; Hardisson C; Salas JA
    J Gen Microbiol; 1984 Nov; 130(11):2883-91. PubMed ID: 6084703
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hypolipidemic activity of rifamycin derivatives.
    Traxler P; Kump W; Mueller K; Tosch W
    J Med Chem; 1990 Feb; 33(2):552-60. PubMed ID: 2299623
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Oxygen Enhancement of bactericidal activity of rifamycin SV on Escherichia coli and aerobic oxidation of rifamycin SV to rifamycin S catalyzed by manganous ions: the role of superoxide.
    Kono Y
    J Biochem; 1982 Jan; 91(1):381-95. PubMed ID: 6279585
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of an exotoxin from Bacillus thuringiensis on deoxyribonucleic acid-dependent ribonucleic acid polymerase in nuclei from adult Sarcophaga bullata. Unusual behaviour of eukaryotic polymerases to inhibitors.
    Beebee TJ; Bond RP
    Biochem J; 1973 Sep; 136(1):9-13. PubMed ID: 4797897
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In vitro activity of novel rifamycins against rifamycin-resistant Staphylococcus aureus.
    Murphy CK; Mullin S; Osburne MS; van Duzer J; Siedlecki J; Yu X; Kerstein K; Cynamon M; Rothstein DM
    Antimicrob Agents Chemother; 2006 Mar; 50(3):827-34. PubMed ID: 16495239
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.